Literature DB >> 19507254

Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases.

Annette Lake1, Lesley A Shield, Pablo Cordano, Daniel T Y Chui, Julie Osborne, Shauna Crae, Katherine S Wilson, Sabrina Tosi, Samantha J L Knight, Stefan Gesk, Reiner Siebert, Ron T Hay, Ruth F Jarrett.   

Abstract

A consistent feature of the Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) is the constitutive activation of NF-kappaB transcription factors. In Epstein-Barr virus (EBV)-associated cases of cHL, expression of viral antigens most probably leads to NF-kappaB activation but for non-EBV-associated cases, the mechanism is not clear. Previous small studies have demonstrated deleterious mutations of NFKBIA, the gene encoding IkappaB alpha, in HRS cells. In the present study, we aimed to establish the frequency of NFKBIA mutation in cHL by investigating a larger series of cases and to determine whether these mutations are a characteristic feature of non-EBV-associated cHL. Single HRS cells from 20 cases of cHL were analysed by PCRs covering all 6 exons of the gene. Clonal deleterious mutations were detected in 3 cases and in 1 case both alleles of the gene were shown to harbour mutations. NFKBIA mutations were detected only in non-EBV-associated cases but the majority of these cases had wild-type NFKBIA. It remains possible that defects in genes encoding other inhibitors of NF-kappaB, such as TNFAIP3 (A20) and CYLD, are involved in the latter cases, as described for one case in this series. 2009 UICC

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19507254     DOI: 10.1002/ijc.24502

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

Review 1.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

2.  NFKBIA deletion in glioblastomas.

Authors:  Markus Bredel; Denise M Scholtens; Ajay K Yadav; Angel A Alvarez; Jaclyn J Renfrow; James P Chandler; Irene L Y Yu; Maria S Carro; Fangping Dai; Michael J Tagge; Roberto Ferrarese; Claudia Bredel; Heidi S Phillips; Paul J Lukac; Pierre A Robe; Astrid Weyerbrock; Hannes Vogel; Steven Dubner; Bret Mobley; Xiaolin He; Adrienne C Scheck; Branimir I Sikic; Kenneth D Aldape; Arnab Chakravarti; Griffith R Harsh
Journal:  N Engl J Med       Date:  2010-12-22       Impact factor: 91.245

3.  Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.

Authors:  Enrico Tiacci; Erik Ladewig; Gianluca Schiavoni; Alex Penson; Elisabetta Fortini; Valentina Pettirossi; Yuchun Wang; Ariele Rosseto; Alessandra Venanzi; Sofija Vlasevska; Roberta Pacini; Simonetta Piattoni; Alessia Tabarrini; Alessandra Pucciarini; Barbara Bigerna; Alessia Santi; Alessandro M Gianni; Simonetta Viviani; Antonello Cabras; Stefano Ascani; Barbara Crescenzi; Cristina Mecucci; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  Blood       Date:  2018-04-12       Impact factor: 22.113

4.  Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.

Authors:  Susan Heavey; Peter Godwin; Anne-Marie Baird; Martin P Barr; Kazuo Umezawa; Sinéad Cuffe; Stephen P Finn; Kenneth J O'Byrne; Kathy Gately
Journal:  Cancer Biol Ther       Date:  2014-07-15       Impact factor: 4.742

5.  Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.

Authors:  Angélica María Gamboa-Cedeño; Mariángeles Castillo; Wenming Xiao; Thomas A Waldmann; Stella Maris Ranuncolo
Journal:  J Cancer Res Clin Oncol       Date:  2019-04-02       Impact factor: 4.553

Review 6.  Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.

Authors:  Kian-Huat Lim; Yibin Yang; Louis M Staudt
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 7.  Hodgkin lymphoma.

Authors:  Ralf Küppers; Andreas Engert; Martin-Leo Hansmann
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

8.  A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.

Authors:  Wei Wei; Yuquan Lin; Zhihui Song; Wenming Xiao; Liqi Chen; Jiejing Yin; Yan Zhou; Stefan K Barta; Michael Petrus; Thomas A Waldmann; Yibin Yang
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 12.531

9.  Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma.

Authors:  Stephen J Salipante; Andrew Adey; Anju Thomas; Choli Lee; Yajuan J Liu; Akash Kumar; Alexandra P Lewis; David Wu; Jonathan R Fromm; Jay Shendure
Journal:  Genes Chromosomes Cancer       Date:  2015-12-09       Impact factor: 5.006

10.  Mutations in the genes coding for the NF-κB regulating factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma.

Authors:  Martin A Schumacher; Roland Schmitz; Verena Brune; Enrico Tiacci; Claudia Döring; Martin-Leo Hansmann; Reiner Siebert; Ralf Küppers
Journal:  Haematologica       Date:  2009-07-31       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.